이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

신경내분비종양에서 루타테라와 ASTX727 (LANTana)

2026년 11월 11일 업데이트: Imperial College London

전이성 신경내분비종양 환자에서 Lutathera 치료 결과 개선을 위한 Somatostatin Receptor-2의 후생적 변형

Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus.

연구 개요

상세 설명

Patients with neuroendocrine tumours (NET) who are found to be eligible will receive up to 4 doses of Lutathera on this trial. All participants will receive ASTX727 orally (cedazuridine 100mg + 35mg decitabine) Days 0-5 prior to receiving Lutathera Day 8 +/- 2days. Each cycle will be repeated every 2 months for 4 cycles unless unacceptable toxicity, progression of disease or withdrawal of patients' consent. Restaging will occur after 2 cycles of Lutathera and at the end of treatment. Patients will be followed 3 monthly until disease progression, death or withdrawal of patients' consent.

연구 유형

중재적

등록 (추정된)

37

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • London, City of
      • London, London, City of, 영국, W12 0HS
        • 모병
        • Hammersmith Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Be willing and able to provide written informed consent for the trial.

  2. Be aged 18 or over at the day of signing consent

  3. Histologic or cytologic confirmed diagnosis of neuroendocrine tumour

  4. Have archival tissue block available or willing to have fresh tissue biopsy if blocks not available

  5. Have disease that can be readily biopsied by ultrasound guidance (n=5)

  6. Ki67 < 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months)

  7. Progression or intolerance to first line therapy including somatostatin analogues

  8. ECOG Performance status 0 - 2

  9. No tumoural uptake on [68Ga]-DOTA-TATE or uptake less than background liver

  10. Measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

  11. Adequate organ function as outlined in the protocol

  12. Women of childbearing potential must be willing to use a highly effective method of contraception as outlined in the protocol for the course of the study through 6 months after the last dose of Investigational Medicinal Product (IMP).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects

  13. Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

    Expansion Cohort (n=10 participants):

  14. <50% disease occupation of liver

Exclusion Criteria:

  1. Previous treatment with either study medication and/or known hypersensitivity to the study medication
  2. Serious concurrent medical illness, including serious active infection
  3. History of organ transplant
  4. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.
  5. Has a known history of active Bacillus Tuberculosis (TB).
  6. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  7. Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage
  8. Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP.
  9. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  12. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP.
  13. Has received a live vaccine within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  14. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
  15. Other clinically significant co-morbidities that could compromise the subject's participating in the study

Expansion Cohort (n=10 participants):

15. > 2 lines of previous therapy, excluding somatostatin analogues

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 치료

Cedazuridine 100mg + 35mg decitabine

Peptide receptor radionuclide therapy (PRRT)

다른 이름들:
  • 루테튬 Lu 177 dotatate
다른: Expansion Cohort

Cedazuridine 100mg + 35mg decitabine

Peptide receptor radionuclide therapy (PRRT)

다른 이름들:
  • 루테튬 Lu 177 dotatate

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using [68Ga]-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera
기간: Through study completion, an average of 1 year

This outcome will be assessed using a specific PET scan

Through study completion, an average of 1 year

2차 결과 측정

결과 측정
측정값 설명
기간
To assess tolerability of combination therapy
기간: Through study completion, an average of 1 year

This outcome will be assessed using CTCAE v5.0

Through study completion, an average of 1 year
To assess response to treatment using conventional imaging
기간: Through study completion, an average of 1 year

This outcome will be assessed using standard of care CT scans

Through study completion, an average of 1 year
To assess patients quality of life during treatment
기간: Through study completion, an average of 1 year

This will be assessed using standardised quality of life questionnaires, which will be given to the patients

Through study completion, an average of 1 year
To assess progression free survival
기간: Through study completion, an average of 1 year

This will be the time until patients show progressive disease on their routine CT scans

Through study completion, an average of 1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Rohini Sharma, Professor, Imperial College London

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 4월 25일

기본 완료 (추정된)

2027년 5월 30일

연구 완료 (추정된)

2030년 1월 30일

연구 등록 날짜

최초 제출

2021년 12월 3일

QC 기준을 충족하는 최초 제출

2021년 12월 16일

처음 게시됨 (실제)

2022년 1월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다